Enzymatic UDP-Galactose Production via Substrate Extraction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing UDP-galactose are costly and inefficient, relying on expensive substrates and enzymes that are difficult to scale up and regulate, particularly for industrial and pharmaceutical applications.
Innovation Solution
An enzyme-catalyzed process using uridine monophosphate (UMP) and D-galactose as starting materials, with a cascade reaction involving galactokinase, polyphosphate kinase, and glucose-1-phosphate uridylyltransferase to produce UDP-galactose, eliminating the need for expensive uridine triphosphate and reducing the number of required enzymes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If traditional methods using expensive substrates and enzymes are used, then UDP-galactose can be produced, but production costs are very high and scalability is limited
Solution Approach 1:
The patent changes the chemical parameters of the reaction system by using alternative substrates (D-galactose instead of UDP-glucose) and optimizing enzyme conditions to achieve both low cost and high productivity. The new substrate combination reduces material costs while the optimized enzymatic cascade enables scalable production.
Solution Approach 2:
The patent extracts and eliminates the expensive UDP-glucose substrate from the traditional synthesis pathway, replacing it with cheaper D-galactose. This removal of the costly component directly addresses both the cost and scalability issues simultaneously.
2Productivity
If enzymes are immobilized on Ni NTA agarose beads, then UDP-Gal production is enabled, but enzymes are weakly bound and rapidly washed off in high ionic strength reaction mixtures
Solution Approach 1:
Instead of using expensive and unstable Ni NTA agarose beads, the patent employs cheaper, more stable immobilization supports that maintain enzyme activity throughout the reaction. The enzymes are firmly bound and do not leach, making the system reliable for industrial application.
Solution Approach 2:
The patent uses composite immobilization systems combining appropriate support materials with enzyme complexes that maintain stability in high ionic strength conditions, preventing enzyme wash-off while enabling continuous production.
3Device complexity
If Ni agarose beads are used for enzyme immobilization, then enzyme support is provided, but nickel ions are released to the solution causing toxicity
Solution Approach 1:
The patent removes nickel-containing materials from the system entirely, replacing them with nickel-free immobilization supports. This elimination of the toxic element solves the toxicity problem while maintaining the functional benefits of enzyme immobilization.
Solution Approach 2:
The patent replaces expensive nickel-based immobilization systems with cheaper, biocompatible alternatives that do not release toxic ions, making the system suitable for food and pharmaceutical applications.
4Productivity
If a 7 enzyme cascade is used starting from expensive glucose 1-phosphate and UDP-glucose, then UDP-Gal can be produced, but the overall yield is only 35% and starting materials are expensive
Solution Approach 1:
The patent extracts and removes the expensive UDP-glucose and glucose 1-phosphate starting materials from the traditional 7-enzyme cascade, replacing them with inexpensive D-galactose. This fundamentally changes the material input requirements.
Solution Approach 2:
Instead of building up to UDP-galactose through multiple phosphorylation and activation steps from glucose, the patent inverts the approach by directly using D-galactose as the starting point, significantly reducing both the number of steps and material costs.
5Ease of manufacture
If glucose 1-phosphate and UDP-glucose are used as substrates, then UDP-Gal synthesis is enabled, but substrate cost is very high
Solution Approach 1:
The patent removes the expensive substrates (glucose 1-phosphate and UDP-glucose) from the reaction system and replaces them with inexpensive D-galactose, directly addressing the substrate cost issue while maintaining manufacturability.
Solution Approach 2:
The patent changes the substrate parameters from expensive activated sugars to inexpensive native D-galactose, fundamentally altering the cost structure of the production process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves yields above 99% and significantly reduces production costs, allowing for large-scale, cost-effective production of UDP-galactose suitable for industrial and pharmaceutical applications.
Implementation Method 1
forming galactose 1-phosphate from D-galactose and adenosine triphosphate being catalyzed by a galactokinase
Implementation Method 2
forming galactose 1-phosphate from D-galactose and adenosine triphosphate
Implementation Method 3
forming uridine triphosphate from uridine monophosphate, adenosine triphosphate and polyphosphate being catalyzed by a uridine monophosphate kinase and a polyphosphate kinase
Implementation Method 4
forming uridine triphosphate from uridine monophosphate, adenosine triphosphate and polyphosphate
Implementation Method 5
reacting galactose 1-phosphate with uridine triphosphate to UDP-galactose in the presence of a glucose-1-phosphate uridylyltransferase
Implementation Method 6
reacting galactose 1-phosphate with uridine triphosphate to UDP-galactose
Data Source
AI summary
The present invention relates to an enzyme-catalyzed process for producing UDP-galactose from low-cost substrates uridine monophosphate and D-galactose in a single reaction mixture. The process can be operated (semi)continuously or in batch mode. The process can be extended to uridine as starting material instead of uridine monophosphate. Further, the process can be adapted to produce galactosylated molecules and biomolecules including saccharides, proteins, peptides, glycoproteins or glycopeptides, particularly human milk oligosaccharides (HMO) and (monoclonal) antibodies.